Comparison of Efficacy of Intravenous Versus Intramuscular Injection Meglumine Antimoniate in patients of Cutaneous Leishmaniasis

Phase 3

Recruiting

• Conditions: cutaneous leishmaniaisis.; Cutaneous leishmaniasis; B55.1

• Registration Number: IRCT20210823052264N4
• Lead Sponsor: CMH Quetta

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

All patients with biopsy proven leishmaniasis plus any of the following: has lesion(s) located in sites not compatible with local treatment for example eyelids
lesions in which scaring would be disabling or severely disfiguring like on face
lesions that will have difficulting in healing like on lower limb or over a joint
lesions involving mucosa or cartilage
lesion =4 cm
lesion with sporotrichoid spread
multiple lesions

Exclusion Criteria

patients allergic to antimonials
the lesion is already self-curing
pregnant and breast feeding women
those who refused to accept the diagnostic procedures
patients having mucosal, mucocutaneous or visceral leishmaniasis
Patients with comorbidity (diabetes, hypertension,chronic liver disease,chronic kidney disease) and/or immunosuppression
Patients with baseline ECG abnormalities/Heart disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Healing of lesion in response to treatment. Timepoint: before intervention and 2, 4 , 6 and 8 weeks after intervention until complete healing occur than patient called for followup after 4 weeks. Method of measurement: Clinical Response Evaluation.